PL2739628T3 - Nowe makrocykle jako inhibitory czynnika xia - Google Patents
Nowe makrocykle jako inhibitory czynnika xiaInfo
- Publication number
- PL2739628T3 PL2739628T3 PL12762427T PL12762427T PL2739628T3 PL 2739628 T3 PL2739628 T3 PL 2739628T3 PL 12762427 T PL12762427 T PL 12762427T PL 12762427 T PL12762427 T PL 12762427T PL 2739628 T3 PL2739628 T3 PL 2739628T3
- Authority
- PL
- Poland
- Prior art keywords
- factor xia
- xia inhibitors
- novel macrocycles
- macrocycles
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515401P | 2011-08-05 | 2011-08-05 | |
| EP12762427.8A EP2739628B1 (en) | 2011-08-05 | 2012-08-06 | Novel macrocycles as factor xia inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2739628T3 true PL2739628T3 (pl) | 2017-11-30 |
Family
ID=46889416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12762427T PL2739628T3 (pl) | 2011-08-05 | 2012-08-06 | Nowe makrocykle jako inhibitory czynnika xia |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9221818B2 (pl) |
| EP (1) | EP2739628B1 (pl) |
| JP (1) | JP6158181B2 (pl) |
| CN (1) | CN103857681B (pl) |
| AR (1) | AR088748A1 (pl) |
| BR (1) | BR112014002202A2 (pl) |
| CA (1) | CA2844254A1 (pl) |
| CY (1) | CY1119281T1 (pl) |
| DK (1) | DK2739628T3 (pl) |
| EA (1) | EA024791B1 (pl) |
| ES (1) | ES2635088T3 (pl) |
| HR (1) | HRP20171122T1 (pl) |
| HU (1) | HUE034487T2 (pl) |
| LT (1) | LT2739628T (pl) |
| MX (1) | MX345763B (pl) |
| PL (1) | PL2739628T3 (pl) |
| PT (1) | PT2739628T (pl) |
| RS (1) | RS56244B1 (pl) |
| SI (1) | SI2739628T1 (pl) |
| TW (1) | TW201311689A (pl) |
| WO (1) | WO2013022818A1 (pl) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160841A1 (es) | 2010-02-11 | 2016-09-10 | Bristol Myers Squibb Co | Macrociclos como inhibidores del factor de coagulacion (fxia) |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| EP3309148A1 (en) | 2011-10-14 | 2018-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| JP6033318B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| ES2572908T3 (es) | 2011-10-14 | 2016-06-03 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa |
| CA2880866A1 (en) | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
| US20140038969A1 (en) | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
| EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2014059202A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2906551B1 (en) | 2012-10-12 | 2018-02-28 | Bristol-Myers Squibb Company | Crystalline forms of a factor xia inhibitor |
| EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| US9809545B2 (en) | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| FR3010076B1 (fr) * | 2013-09-02 | 2016-12-23 | Centre Nat De La Rech Scient - Cnrs - | Inhibiteurs de metalloproteases, leurs procedes de preparation et leurs utilisations therapeutiques |
| LT3099687T (lt) * | 2014-01-31 | 2018-09-10 | Bristol-Myers Squibb Company | Makrociklai su heterociklinėmis p2' grupėmis kaip faktoriaus xia inhibitoriai |
| NO2760821T3 (pl) | 2014-01-31 | 2018-03-10 | ||
| US9676723B2 (en) | 2014-02-11 | 2017-06-13 | Merck Sharp & Dohme Corp | Factor XIa inhibitors |
| WO2015123093A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| EP3134408B1 (en) | 2014-04-22 | 2020-08-12 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| WO2016015593A1 (en) | 2014-07-28 | 2016-02-04 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| JP6526796B2 (ja) * | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｆｘｉａ阻害剤であるジアミドマクロ環 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (pl) * | 2014-10-01 | 2018-10-20 | ||
| EP3310777B1 (en) * | 2015-06-19 | 2019-10-09 | Bristol-Myers Squibb Company | Diamide macrocycles as factor xia inhibitors |
| JP6816103B2 (ja) | 2015-07-29 | 2021-01-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 非芳香族性Ｐ２’基を担持する新規大員環の第ＸＩａ因子阻害剤 |
| WO2017019819A1 (en) | 2015-07-29 | 2017-02-02 | Bristol-Myers Squibb Company | Factor xia macrocyclic inhibitors bearing alkyl or cycloalkyl p2' moieties |
| HUE057106T2 (hu) | 2015-10-01 | 2022-04-28 | Biocryst Pharm Inc | Humán plazma kallikrein gátlók |
| WO2017074833A1 (en) | 2015-10-29 | 2017-05-04 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use |
| KR20180073602A (ko) * | 2015-10-29 | 2018-07-02 | 머크 샤프 앤드 돔 코포레이션 | 인자 XIa 억제제 |
| CN109195973A (zh) | 2016-03-02 | 2019-01-11 | 百时美施贵宝公司 | 具有因子xia抑制活性的二酰胺大环类化合物 |
| US20190135761A1 (en) * | 2016-05-10 | 2019-05-09 | Solvay Sa | Composition comprising 3-(haloalkyl or formyl)-1h-pyrazole-4-carboxylic acids or esters, its manufacture and its use for the preparation of carboxamides |
| US10143681B2 (en) | 2016-08-22 | 2018-12-04 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| EP3309143A1 (en) * | 2016-10-17 | 2018-04-18 | Solvay SA | Method for producing fluoroformate compounds |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| CN107011275A (zh) * | 2017-03-31 | 2017-08-04 | 深圳市众康动保科技有限公司 | 一种1,4,5‑三取代‑1,2,3‑三氮唑类化合物的合成方法 |
| WO2019011166A1 (zh) * | 2017-07-14 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | 大环酰胺化合物及其药物组合物和用途 |
| KR20220002966A (ko) | 2019-04-16 | 2022-01-07 | 메드샤인 디스커버리 아이엔씨. | XIa 인자 억제제로서의 거대고리 유도체 |
| WO2021013209A1 (zh) | 2019-07-23 | 2021-01-28 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| EP4054720A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| IL297832A (en) | 2020-05-05 | 2023-01-01 | Nuvalent Inc | Macrocyclic heteroaromatic chemotherapeutic agents |
| AU2021268345A1 (en) | 2020-05-05 | 2022-11-10 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| EP4214209A1 (en) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
| CN112920005B (zh) * | 2021-01-31 | 2022-06-14 | 上海李氏化学科技有限公司 | 一种(r)-3-(3-氯-2-氟苯)-4,5-二氢异噁唑-5-羧酸的制备方法 |
| PE20240089A1 (es) * | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
| IL308193A (en) * | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors |
| CN113336715B (zh) * | 2021-08-04 | 2021-11-23 | 山东海利尔化工有限公司 | 一种含二氧戊环的三唑类化合物及其中间体的制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| CA2383008A1 (en) | 1999-06-14 | 2000-12-21 | Amanda Jane Lyons | Compounds |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| WO2003011222A2 (en) | 2001-07-27 | 2003-02-13 | Merck & Co., Inc. | Thrombin inhibitors |
| DE60233335D1 (de) | 2001-09-21 | 2009-09-24 | Bristol Myers Squibb Co | Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) * | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| US7459564B2 (en) | 2005-01-13 | 2008-12-02 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor XIa inhibitors |
| US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
| WO2007070816A2 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Thiophene derivatives as factor xia inhibitors |
| WO2007070818A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2007070826A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| AR058380A1 (es) | 2005-12-23 | 2008-01-30 | Bristol Myers Squibb Co | Inhibidores del factor viia macrociclicos utiles como anticoagulantes |
| US20080099168A1 (en) | 2006-10-26 | 2008-05-01 | Kou-Chang Liu | Soft and absorbent tissue products |
| WO2008076805A2 (en) | 2006-12-15 | 2008-06-26 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| TW200848024A (en) | 2007-06-13 | 2008-12-16 | Bristol Myers Squibb Co | Dipeptide analogs as coagulation factor inhibitors |
| US8324199B2 (en) | 2008-03-13 | 2012-12-04 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| PE20160841A1 (es) * | 2010-02-11 | 2016-09-10 | Bristol Myers Squibb Co | Macrociclos como inhibidores del factor de coagulacion (fxia) |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| ES2572908T3 (es) | 2011-10-14 | 2016-06-03 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa |
| JP6033318B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| EP3309148A1 (en) | 2011-10-14 | 2018-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| CA2880866A1 (en) | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
| US20140038969A1 (en) | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
| EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2906551B1 (en) | 2012-10-12 | 2018-02-28 | Bristol-Myers Squibb Company | Crystalline forms of a factor xia inhibitor |
| WO2014059202A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
-
2012
- 2012-08-03 TW TW101128173A patent/TW201311689A/zh unknown
- 2012-08-06 JP JP2014524152A patent/JP6158181B2/ja active Active
- 2012-08-06 HU HUE12762427A patent/HUE034487T2/en unknown
- 2012-08-06 LT LTEP12762427.8T patent/LT2739628T/lt unknown
- 2012-08-06 PT PT127624278T patent/PT2739628T/pt unknown
- 2012-08-06 EA EA201490418A patent/EA024791B1/ru not_active IP Right Cessation
- 2012-08-06 BR BR112014002202A patent/BR112014002202A2/pt not_active Application Discontinuation
- 2012-08-06 WO PCT/US2012/049706 patent/WO2013022818A1/en active Application Filing
- 2012-08-06 RS RS20170852A patent/RS56244B1/sr unknown
- 2012-08-06 CN CN201280049108.9A patent/CN103857681B/zh active Active
- 2012-08-06 DK DK12762427.8T patent/DK2739628T3/en active
- 2012-08-06 ES ES12762427.8T patent/ES2635088T3/es active Active
- 2012-08-06 US US14/236,973 patent/US9221818B2/en active Active
- 2012-08-06 EP EP12762427.8A patent/EP2739628B1/en active Active
- 2012-08-06 SI SI201231004T patent/SI2739628T1/sl unknown
- 2012-08-06 PL PL12762427T patent/PL2739628T3/pl unknown
- 2012-08-06 CA CA2844254A patent/CA2844254A1/en not_active Abandoned
- 2012-08-06 MX MX2014000831A patent/MX345763B/es active IP Right Grant
- 2012-08-07 AR ARP120102878A patent/AR088748A1/es unknown
-
2015
- 2015-11-16 US US14/942,013 patent/US9611274B2/en active Active
-
2017
- 2017-02-21 US US15/437,605 patent/US9902742B2/en active Active
- 2017-07-21 HR HRP20171122TT patent/HRP20171122T1/hr unknown
- 2017-09-04 CY CY20171100930T patent/CY1119281T1/el unknown
-
2018
- 2018-01-25 US US15/879,619 patent/US10208068B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AR088748A1 (es) | 2014-07-02 |
| US20170158712A1 (en) | 2017-06-08 |
| US20160068544A1 (en) | 2016-03-10 |
| HUE034487T2 (en) | 2018-02-28 |
| PT2739628T (pt) | 2017-08-02 |
| CY1119281T1 (el) | 2018-02-14 |
| EA201490418A1 (ru) | 2014-05-30 |
| US9611274B2 (en) | 2017-04-04 |
| WO2013022818A1 (en) | 2013-02-14 |
| BR112014002202A2 (pt) | 2017-03-07 |
| US20180148461A1 (en) | 2018-05-31 |
| CN103857681A (zh) | 2014-06-11 |
| RS56244B1 (sr) | 2017-11-30 |
| US10208068B2 (en) | 2019-02-19 |
| EP2739628A1 (en) | 2014-06-11 |
| CA2844254A1 (en) | 2013-02-14 |
| US9902742B2 (en) | 2018-02-27 |
| CN103857681B (zh) | 2017-07-14 |
| ES2635088T3 (es) | 2017-10-02 |
| MX2014000831A (es) | 2014-02-27 |
| US9221818B2 (en) | 2015-12-29 |
| US20140221338A1 (en) | 2014-08-07 |
| MX345763B (es) | 2017-02-15 |
| EA024791B1 (ru) | 2016-10-31 |
| JP6158181B2 (ja) | 2017-07-05 |
| JP2014521701A (ja) | 2014-08-28 |
| HRP20171122T1 (hr) | 2017-10-06 |
| LT2739628T (lt) | 2017-08-25 |
| TW201311689A (zh) | 2013-03-16 |
| DK2739628T3 (en) | 2017-09-11 |
| SI2739628T1 (sl) | 2017-08-31 |
| EP2739628B1 (en) | 2017-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2739628T1 (sl) | Novi makrocikli kot faktor xia inhibitorji | |
| ZA201206758B (en) | Macrocycles as factor xia inhibitors | |
| IL237011A0 (en) | Dihydropyridone p1 as factor xia inhibitors | |
| IL237012A0 (en) | Dihydropyridone p1 as factor xia inhibitors | |
| EP2738170A4 (en) | HETEROCYCLIC COMPOUND | |
| IL229513A0 (en) | imidazopyridine compounds | |
| SG11201401021TA (en) | Pyrrolobenzodiazepines | |
| EP2706852A4 (en) | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | |
| GB201109763D0 (en) | Compounds | |
| GB201106395D0 (en) | Compounds | |
| EP2709609A4 (en) | HETEROCYCLIC COMPOUNDS | |
| GB201122139D0 (en) | Compounds | |
| GB201107197D0 (en) | Compounds | |
| HK1200314A1 (en) | R()-n-methyl-propargyl-aminoindan r()-n--- | |
| HK1200315A1 (en) | R()-n-formyl-propargyl-aminoindan r()-n--- | |
| HK1191326A1 (en) | Azaspirodecanone compounds | |
| GB201110938D0 (en) | Compounds | |
| GB201105659D0 (en) | Compounds | |
| GB201118613D0 (en) | Compounds | |
| GB201120805D0 (en) | Compounds | |
| GB201119745D0 (en) | Compounds | |
| GB201119703D0 (en) | Compounds | |
| GB201115829D0 (en) | Compounds | |
| GB201115828D0 (en) | Compounds | |
| GB201115827D0 (en) | Compounds |